Power Up Dispersion
Levagen®+ is a cold water dispersible palmitoylethanolamide (PEA). Utilising patented LipiSperse® delivery system technology it is specifically formulated to overcome the traditional dispersion issues of PEA.
Our award-winning LipiSperse® is scientifically proven to increase bioavailability and functionality of PEA. Levagen®+ has been shown to be absorbed within 45 minutes, with x1.75 the absorption than standard PEA.
PEA influences the endocannabinoid system, and thereby is considered a safe and clinically-proven alternative to CBD.
Levagen®+ advantages
superior bioavailability to standard PEA
safe alternative to CBD
convenient format options
clinically studied and proven
non-GMO, gluten free, allergen free, Gencor self-affirmed GRAS
Informed-Ingredient Certified by LGC-to be WADA-banned substances free
multi award winning
utilising patent LipiSperse® technology
Australian made
Migraine
Headaches typically can last between 2 to 24 hours, with most migraine headaches lasting about 4 hours. The study explored PEA as a safe and effective alternative in reducing pain and duration.
Allergic Rhinitis
AR is an inflammatory, symptomatic disorder that is stimulated by allergens. This study evaluated the efficacy of PEA, as an alternative treatment for these symptoms.
Alternative to Ibuprofen
This study assessed the efficacy of Levagen®+ for reducing the severity and duration of acute episodes of tension-type headaches when compared to treatment with ibuprofen.
Inflammation responses post Covid-19
This study examined the effects of PEA on pro-inflammatory biomarkers in adults recently diagnosed with COVID-19 who were unvaccinated and non hospitalized.
Joint Pain
This study aimed to assess the efficacy of PEA, for alleviating joint pain and improving quality of life.
Sleep Disturbance
This study aimed to asses the efficacy of PEA supplementation on sleep quality in adults with sleep pattern disturbance.
Knee osteoarthritis pain and other symptoms
The study was to assess the safety, tolerability and efficacy of PEA when dosed at 300mg and 600mg per day on symptoms of knee osteoarthritis.
Muscle recovery
The study aimed to compare the bioavailability of a single dose of Levagen®+ (PEA + LipiSperse®) in an Exercise Study, demonstrating Levagen®+ aids in muscle recovery.
Increased absorption of PEA using LipiSperse®
LipiSperse® dispersion technology as Levagen®+ (PEA) has been used in a pharmacokinetic study to evaluate the absorption of palmitoylethanolamide.
Best Sports Nutrition Ingredient of the Year
Most Exciting Partnership - Gencor & Gloucester Rugby Levagen®+ and HydroCurc®
Ingredient of the Year Healthy Ageing - USA
Research Project of the Year - Asia
Levagen is a registered trademark of Gencor Pacific Ltd
LipiSperse is a patented technology and trademark owned exclusively by Pharmako Biotechnologies Pty.Ltd., registered in Australia and other countries.